Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
Volume 39 Issue 1
Jan.  2021
Turn off MathJax
Article Contents

LUO Chuan, MA Jianjiang, MIAO Zhenyuan, WU Yuelin. Design, synthesis and antitumor activity of 3-arenobufagin esters[J]. Journal of Pharmaceutical Practice and Service, 2021, 39(1): 35-37, 57. doi: 10.12206/j.issn.1006-0111.202007022
Citation: LUO Chuan, MA Jianjiang, MIAO Zhenyuan, WU Yuelin. Design, synthesis and antitumor activity of 3-arenobufagin esters[J]. Journal of Pharmaceutical Practice and Service, 2021, 39(1): 35-37, 57. doi: 10.12206/j.issn.1006-0111.202007022

Design, synthesis and antitumor activity of 3-arenobufagin esters

doi: 10.12206/j.issn.1006-0111.202007022
  • Received Date: 2020-07-06
  • Rev Recd Date: 2020-09-28
  • Publish Date: 2021-01-25
  •   Objective  To search for novel potent 3-ester derivatives of arenobufagin and test their antitumor activities in vitro.  Methods  Target compounds were synthesized by esterification of arenobufagin with acids. CellTiter method was used to assay the in vitro antitumor activities.  Results   3-Ester derivatives exhibited excellent antitumor activities against all the cancer cells.  Conclusion  Among the 3-ester derivatives, compound 2a had the best activities with the IC50 of 4.0−91.7 nmol/L and appeared to be a valuable candidate for further study.
  • [1] 秦资凡, 王保和. 中药蟾酥的研究进展概况[J]. 中国药物评价, 2014, 31(5):306-309. doi:  10.3969/j.issn.2095-3593.2014.05.016
    [2] 吴喜燕, 高慧敏, 王智民. 蟾蜍类药材化学成分研究进展[J]. 中国实验方剂学杂志, 2010, 16(14):207-214, 220. doi:  10.3969/j.issn.1005-9903.2010.14.066
    [3] NOGAWA T, KAMANO Y, YAMASHITA A, et al. Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su[J]. J Nat Prod,2001,64(9):1148-1152. doi:  10.1021/np0101088
    [4] HOU W, HUANG Z X, XU H G, et al. Hybrids of arenobufagin and benzoisoselenazol reducing the cardiotoxicity of arenobufagin[J]. Bioorg Med Chem Lett,2018,28(20):3391-3394. doi:  10.1016/j.bmcl.2018.08.038
    [5] HAN L Y, YUAN B, SHIMADA R, et al. Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87[J]. Int J Oncol,2018,53(6):2488-2502.
    [6] PERERA CÓRDOVA W H, LEITÃO S G, CUNHA-FILHO G, et al. Bufadienolides from parotoid gland secretions of Cuban toad Peltophryne fustiger (Bufonidae): Inhibition of human kidney Na(+)/K(+)-ATPase activity[J]. Toxicon,2016,110:27-34. doi:  10.1016/j.toxicon.2015.11.015
    [7] WEI X, YANG J, MAO Y, et al. Arenobufagin inhibits the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway and induces apoptosis and autophagy in pancreatic cancer cells[J]. Pancreas,2020,49(2):261-272. doi:  10.1097/MPA.0000000000001471
    [8] MA B, XIAO Z Y, CHEN Y J, et al. Synthesis and structure-activity relationships study of cytotoxic bufalin 3-nitrogen-containing-ester derivatives[J]. Steroids,2013,78(5):508-512. doi:  10.1016/j.steroids.2013.02.007
    [9] DENG L J, WANG L H, PENG C K, et al. Fibroblast activation protein α activated tripeptide bufadienolide antitumor prodrug with reduced cardiotoxicity[J]. J Med Chem,2017,60(13):5320-5333. doi:  10.1021/acs.jmedchem.6b01755
    [10] 果德安, 吴婉莹, 栗世铀, 等. 沙蟾毒精衍生物及其制备方法、包含该衍生物的组合物、及其用途: CN110483608A[P]. 2019-11-22.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Figures(2)  / Tables(1)

Article Metrics

Article views(3109) PDF downloads(29) Cited by()

Related
Proportional views

Design, synthesis and antitumor activity of 3-arenobufagin esters

doi: 10.12206/j.issn.1006-0111.202007022

Abstract:   Objective  To search for novel potent 3-ester derivatives of arenobufagin and test their antitumor activities in vitro.  Methods  Target compounds were synthesized by esterification of arenobufagin with acids. CellTiter method was used to assay the in vitro antitumor activities.  Results   3-Ester derivatives exhibited excellent antitumor activities against all the cancer cells.  Conclusion  Among the 3-ester derivatives, compound 2a had the best activities with the IC50 of 4.0−91.7 nmol/L and appeared to be a valuable candidate for further study.

LUO Chuan, MA Jianjiang, MIAO Zhenyuan, WU Yuelin. Design, synthesis and antitumor activity of 3-arenobufagin esters[J]. Journal of Pharmaceutical Practice and Service, 2021, 39(1): 35-37, 57. doi: 10.12206/j.issn.1006-0111.202007022
Citation: LUO Chuan, MA Jianjiang, MIAO Zhenyuan, WU Yuelin. Design, synthesis and antitumor activity of 3-arenobufagin esters[J]. Journal of Pharmaceutical Practice and Service, 2021, 39(1): 35-37, 57. doi: 10.12206/j.issn.1006-0111.202007022
  • 活性天然产物是药物研发重要的先导化合物来源之一,基于天然产物已成功开发出很多临床治疗药物。从我国传统中药中分离有效活性成分,已成为国内外发现先导化合物的一个有效途径。蟾蜍是我国特有中药材,具有解毒、消肿、止痛、强心利尿、抗癌等作用[1-3]。现代研究发现中药蟾蜍含有多种抗肿瘤活性成分,其中,主要化学成分之一的沙蟾毒精(图1)具有优秀的体内外抗肿瘤活性,但其心脏毒性使得沙蟾毒精治疗窗窄,无法作为抗肿瘤药物进行后续开发[4-7]。早期研究表明,沙蟾毒精的3位羟基对活性和毒性有较大影响[8]。Deng等对沙蟾毒精的3位进行了修饰,设计了一类成纤维细胞活化蛋白-α靶向沙蟾毒精前药衍生物,不仅在体内外显示出优异的抗肿瘤活性,而且降低了心脏毒性[9]。果德安等也对沙蟾毒精的3位羟基进行了结构修饰,设计得到一类3-氮取代氨基甲酸酯类衍生物,对A549、HCT116、Calu-6、PANC-1、SW620和NSCLC等6种细胞株均显示出优秀的活性,其IC50值在10 nmol/L以下[10]。因此,笔者设计3位酯基取代的沙蟾毒精衍生物,进一步探讨沙蟾毒精的构效关系,从中筛选获得高活性的候选化合物。

  • 核磁共振仪为Bruker 300或600型,TMS为内标,CD3OD、DMSO-d6或者CDCl3为溶剂。化学位移(δ)和偶合常数(J)分别以×10−6(ppm)和Hz为单位。在API-3000LC-MS型质谱仪上完成ESI质谱。TLC分析所用硅胶板为GF254(青岛海洋化工有限公司)。硅胶柱层析采用60G硅胶(青岛海洋化工有限公司)。商品化溶剂皆为市售分析纯或化学纯。

  • 将沙蟾毒精(83 mg, 0.2 mmol)、酸(0.3 mmol)、DMAP(24.4 mg, 0.2 mmol)和5 ml干燥的二氯甲烷加入到25 ml烧瓶中,氩气保护下逐份加入EDCI(115 mg, 0.6 mmol)。室温反应过夜,反应完全后蒸去溶剂,残余物经柱色谱纯化后得目标产物2a2j (洗脱剂为二氯甲烷∶甲醇=100∶1)。

    2a: 白色固体,收率13.9%。1H NMR (500 MHz, CDCl3) δ: 7.68 (d, 1H), 7.36 (s, 1H), 6.28 (d,1H), 5.43 (s,1H), 5.18 (d,1H), 4.14 (d, 1H), 4.05 (d, 2H), 3.91 (q, 1H), 2.15 (d, 2H), 2.02~2.11 (m, 1H), 1.86 (m, 9H), 1.40 (s, 4H), 1.26 (d, 2H), 1.14 (s, 3H), 0.97 (s, 3H)。

    2b: 白色固体,收率为55.5%。1H NMR: (CDCl3, 500 MHz) δ: 7.76 (d, 1H), 7.41 (s, 1H), 6.27 (d, 1H), 5.30 (s, 1H), 4.33 (d,1H), 4.11 (d,1H), 3.84 (s, 1H), 2.43 (d, 1H), 2.30 (t, 2H), 2.05~2.09 (m, 2H), 1.86~1.94 (m, 2H), 1.75~1.80 (m, 5H), 1.63~1.73 (m, 4H), 1.45 (d,1H), 1.33~1.44 (m,15H), 1.27 (s, 3H), 0.86~0.88 (m, 3H)。

    2c: 白色固体,收率15.2%。1H NMR (500 MHz, CDCl3) δ: 7.74 (d, 1H), 7.40 (d, 1H), 6.30 (d, 1H), 5.08 (s, 1H), 4.35 (d, 1H), 4.11 (m, 1H), 3.84 (d, 1H), 2.45 (d, 1H), 2.08 (s, 3H), 1.65~1.92 (m, 11H), 1.46~1.53 (m, 1H), 1.26~1.42 (m, 5H), 1.21 (s, 3H), 0.92 (s, 3H)。

    2d: 白色固体,收率46.7%。1H NMR: (CDCl3, 500MHz) δ: 8.85 (s, 1H), 8.40 (m, 2H), 7.62~7.77 (m, 2H), 7.41 (s, 1H), 6.29 (d, 1H), 5.38 (s, 1H), 4.36 (m, 1H), 4.13 (d, 1H), 3.86 (d, 1H), 2.56 (d, 1H), 1.72~2.24 (m, 11 H), 1.32~1.51 (m, 6H), 1.23(s, 3 H), 0.94 (s, 3H)。

    2e: 白色固体,收率43.5%。1H NMR (500 MHz, CDCl3) δ: 7.66~7.74 (m, 1H), 7.37 (d, 1H), 7.08~7.20 (m, 3H), 6.27 (t,1H), 5.30 (s, 1H), 4.36~4.26 (m, 1H), 4.00~4.15 (m, 2H), 3.81 (m, 1H), 3.56 (d, 1H), 2.27~2.41 (m, 3H), 2.04 (m, 2H), 1.80~1.86 (m, 3H), 1.70~1.79 (m, 4H), 1.64 (s, 3H), 1.26~1.42 (m, 6H), 1.18 (s, 1H), 1.13 (s, 1H), 1.01 (d, 1H), 0.91 (d, 3H)。

    2f: 白色固体,收率50.3%。1H NMR (500 MHz, CDCl3) δ: 7.94 (d, 1H), 7.72 (d, 1H), 7.53 (d, 1H), 7.40 (s, 1H), 7.32 (d, 1H), 6.29 (d, 1H), 5.36 (s, 1H), 5.30 (s, 1H), 4.35 (t, 1H), 4.06~4.16 (m, 1H), 3.85 (d, 1H), 2.51 (d, 1H), 1.97~2.13 (m, 3H), 1.74~1.89 (m, 8H), 1.45~1.54 (m, 1H), 1.31~1.45 (m, 3H), 1.25 (s, 1H), 1.21 (s, 3H), 0.93 (s, 3H)。

    2g: 白色固体,收率42.6%。1H NMR (500 MHz, CDCl3) δ: 10.11 (s, 1H), 8.20 (d, 2H), 7.97 (d, 2H), 7.72 (d, 1H), 7.40 (s, 1H), 6.29 (d, 1H), 5.37 (s, 1H), 5.30 (s, 1H), 4.36 (m, 1H), 4.12 (t, 1H), 3.81~3.93 (m, 1H), 2.55 (d, 1H), 2.08 (t, 2H), 1.84~2.00 (m, 4H), 1.76~1.84 (m, 5H), 1.61 (s, 3H), 1.38 (d, 3H), 1.25 (s, 3H), 0.93 (s, 3H)。

    2h: 白色固体,收率12.5%。1H NMR: (CDCl3, 500MHz) δ: 7.73 (m, 1H), 7.40 (s, 1H), 6.27 (d, 1H), 5.23 (s, 1H), 4.35(q, 2H), 4.36~4.40 (m, 1H), 4.04~4.14 (m, 1H), 2.46 (d, 1H), 1.69~2.26(m, 10H), 1.57 (d, 1H), 1.22~1.50 (m, 8H), 1.20 (s, 3H), 0.91 (s, 3H)。

    2i: 白色固体,收率52.3%。1H NMR (500 MHz, CDCl3) δ: 7.74 (m, 1H), 7.61 (d, 1H), 7.42 (s, 1H), 6.79 (s, 2H), 6.38 (d, 1H), 6.32 (d, 1H), 5.32 (s, 1H), 5.23 (s, 1H), 4.37 (m, 1H), 4.08~4.19 (m, 1H), (3.92 (d, 9H), δ3.87 (d, 1H), 2.51 (d, 1H), 1.84 (m,, 10H), 1.40 (t, 3H), 1.28 (s, 3H), 1.25 (s, 3H), 0.95 (s, 3H)。

    2j: 白色固体,收率39.2%。1H NMR (500 MHz, CDCl3) δ: 7.84 (d, 1H), 7.74 (m, 1H), 7.50 (t, 1H), 7.42 (s, 1H), 7.02 (t, 2H), 6.32 (d, 1H), 5.35 (s, 1H), 4.37 (m, 1H), 4.18~4.09 (m, 1H), 3.92 (d, 3H), 3.87 (d, 1H), 2.52 (d,, 1H), 2.09 (d, 1H), 1.78~2.00 (m, 7H), 1.59 (s, 3H), 1.28~1.46 (m, 6H), 1.25 (s, 3H), 0.96 (s, 3H)。

  • 选用人乳腺癌细胞MCF-7、人肝癌细胞Bel7404和人肠癌细胞HCT116,均由海军军医大学药学院冻存和传代。在37 ℃、5 % CO2条件下,用含有10 %的胎牛血清、1 %的青霉素和链霉素的DMEM培养基中传代培养细胞。弃去培养皿中的上层培养基,用PBS洗细胞2次,再加入胰酶,放入培养基中消化1~2 min,待细胞脱壁后,再加入新的培养基,轻轻吹打,使细胞完全脱落,待细胞入5 ml新的培养基,轻轻吹打,用细胞计数法计算细胞浓度,然后接种于96孔板中。将接种完的96孔板放置于37 ℃、5 %的CO2培养箱中孵育过夜,次日细胞即可贴壁。按照不同的实验设计加入不同浓度的药物,每组设3~4个复孔,每孔加入10 µl相应浓度的药物,再将96孔板放入培养箱继续培养。活性测试采用10 % CellTiterTM Blue(Promega, Cat.# G8081/2, US)试剂盒,并在37 ℃、5 % CO2环境下孵育1 h。用酶标仪(Bio Tek, US)测量530/40 nm和590/35 nm处荧光值,计算公式:

    细胞存活率 (%) = [(As−Ab)/(Ac−Ab)]×100%。

    其中,As: 实验组(含有细胞、荧光试剂和化合物的培养基);Ac: 对照组(含有细胞和荧光试剂,不含化合物的培养基);Ab: 空白组(不含细胞、化合物的培养基)。

  • 目标化合物通过各类酸和沙蟾毒精发生酯化反应得到,收率为12.5%~55.5%,合成路线见图2。从反应收率上看,芳香族酯类衍生物收率高于脂肪族类酯类衍生物。例如,化合物2c为乙酸酯衍生物,收率仅为15.2%,而化合物2e为对甲基苄酯衍生物,收率为43.5%。在反应中还发现,水分对反应有较大影响。因此,反应溶剂需要干燥处理,并且反应体系还需保持在无水条件下,才能保证反应顺利进行。

  • 课题组选择3种肿瘤细胞株(MCF-7、Bel7404和HCT116),以沙蟾毒精为阳性对照,采用CellTiter法开展了体外抗肿瘤活性研究,结果见表1。可以看出,3-沙蟾毒精酯类衍生物均具有优异的体外抗肿瘤活性。对MCF-7细胞株,化合物2a2c2j显示出高于阳性对照药沙蟾毒精的活性。对Bel7404细胞株,所有化合物均显示出优异的活性,其中,化合物2a2b2d2e活性最好,其IC50值均在数个纳摩尔,相比沙蟾毒精提高近1000倍。对HCT116细胞株,化合物2e活性最高,其IC50值为4.5 nmol/L,相比沙蟾毒精提高了3.7倍,化合物2b2c与阳性药相当。

    化合物MCF-7Bel 7404HCT 116
    2a0.09170.00400.0489
    2b0.24030.00240.0163
    2c0.04710.04790.0173
    2d0.18170.00480.0279
    2e0.19100.00400.0045
    2f0.19820.02030.2043
    2g0.18870.02120.0605
    2h0.16160.53650.0302
    2i0.14180.02520.0488
    2j0.09680.01680.0258
    沙蟾毒精0.11014.54400.0167

      整体而言,脂肪族酯类化合物活性高于芳香族酯类化合物,例如对MCF-7细胞株,溴乙酸酯衍生物2a的IC50值为91.7 nmol/L,而芳香族酯类化合物除2j外,活性均在100 nmol/L以上。

  • 基于活性天然产物沙蟾毒精骨架,在其3位引入酯基基团,设计合成出10个3-沙蟾毒精酯类衍生物。体外抗肿瘤活性研究发现,所有的化合物对3种肿瘤细胞株MCF-7、Bel7404和HCT116均显示出优异的抗肿瘤活性。其中,化合物2a活性最好,对3种肿瘤细胞株的IC50值均在100 nmol/L以下,可作为抗肿瘤候选化合物进行进一步研究。

Reference (10)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return